Biotech Earnings: Tenax, ADC, and Rapport Report FY 2025 Results
Key Takeaways
- Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics released their full-year 2025 financial results, highlighting critical pipeline milestones and cash runway extensions.
- The reports underscore a pivotal shift toward Phase 3 data readouts and commercial scaling in the specialized biotech sector.
Mentioned
Key Intelligence
Key Facts
- 1Tenax Therapeutics is advancing its Phase 3 LEVEL study for TNX-103 in PH-HFpEF.
- 2ADC Therapeutics reported on Zynlonta commercial progress and LOTIS clinical trial expansions.
- 3Rapport Therapeutics is focusing on RAP-219 for focal epilepsy and peripheral neuropathic pain.
- 4All three companies provided cash runway guidance extending into 2027.
- 5The reports mark the conclusion of the 2025 fiscal year with a focus on 2026 data catalysts.
| Company | |||
|---|---|---|---|
| Tenax Therapeutics | TNX-103 | PH-HFpEF | Phase 3 |
| ADC Therapeutics | Zynlonta | DLBCL | Commercial/Phase 3 |
| Rapport Therapeutics | RAP-219 | Focal Epilepsy | Phase 2 |
Analysis
The simultaneous release of full-year 2025 financial results from Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics provides a comprehensive look at the current state of the mid-cap biotechnology sector. As these companies transition from early-stage discovery into late-stage clinical execution and commercialization, the market is closely watching their ability to manage cash burn while hitting critical regulatory milestones. For Tenax Therapeutics, the focus remains squarely on the advancement of TNX-103 (levosimendan) for the treatment of pulmonary hypertension in patients with heart failure with preserved ejection fraction (PH-HFpEF). This condition represents a significant unmet medical need with no currently approved therapies, positioning Tenax as a potential first-mover in a high-value cardiovascular niche. The company’s corporate update emphasized the progress of its Phase 3 LEVEL study, which is the primary driver of its valuation heading into 2026.
ADC Therapeutics continues to navigate the complex commercial landscape for Zynlonta (loncastuximab tesirine) in the diffuse large B-cell lymphoma (DLBCL) market. The 2025 operational update highlighted the company's efforts to expand Zynlonta’s reach into earlier lines of therapy through the LOTIS-5 and LOTIS-7 trials. For ADC, the challenge is twofold: maintaining revenue growth for its lead product while simultaneously advancing its next-generation antibody-drug conjugate (ADC) pipeline, including ADCT-601 targeting AXL. The company's financial results reflect the high costs associated with late-stage oncology trials, but management has signaled a disciplined approach to capital allocation, prioritizing the most promising clinical assets to ensure a sustainable path to profitability.
The simultaneous release of full-year 2025 financial results from Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics provides a comprehensive look at the current state of the mid-cap biotechnology sector.
Rapport Therapeutics, a more recent entrant to the public markets compared to its peers in this cluster, provided a business update centered on its precision neuroscience platform. The company’s lead candidate, RAP-219, is being developed for focal epilepsy and other neurological disorders by targeting AMPA receptor-associated proteins. Rapport’s 2025 results highlight the successful completion of early-phase trials and the initiation of broader Phase 2 studies. As a company focused on neuromodulators, Rapport represents a broader trend in the industry toward more targeted, site-specific neurological treatments that aim to reduce the systemic side effects common in traditional CNS drugs.
What to Watch
Across all three companies, the common thread is the management of the 'cash runway.' In the current high-interest-rate environment, biotech firms are under increased pressure to demonstrate that their existing capital can carry them through to the next major data catalyst. Tenax, ADC, and Rapport each provided guidance suggesting that their current cash positions are sufficient to fund operations well into 2027, assuming no major clinical setbacks. This transparency is vital for maintaining investor confidence, particularly as the sector faces ongoing volatility. Analysts will be looking for specific data readouts in the second half of 2026 to validate the current valuations and justify further capital raises if necessary.
Looking forward, the success of these three entities will depend on their ability to execute on clinical timelines. For Tenax, the Phase 3 LEVEL data will be a binary event for the stock. For ADC Therapeutics, the trajectory of Zynlonta sales in a competitive oncology market will determine its long-term viability. For Rapport, the clinical validation of its RAP proteins platform could make it an attractive acquisition target for larger pharmaceutical companies looking to bolster their neuroscience portfolios. As 2026 progresses, these companies will remain bellwethers for the health of the specialized biotech ecosystem, reflecting the industry's shift toward precision medicine and targeted therapeutic interventions.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |